A Phase II Trial of Flavopiridol (NSC #649890) in Patients with Previously Untreated Metastatic Androgen-Independent Prostate Cancer

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 924-928

  Liu, Glenn ^a   Gandara, David R ^b   Lara Jr , Primo N ^b   Raghavan, Derek ^c   Doroshow, James H ^d   Twardowski, Przemyslaw ^d   Kantoff, Philip ^e   Oh, William ^e   Kim, KyungMann ^a   Wilding, George ^a,f  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Medical Oncology Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; LOPERAMIDE;

ABDOMINAL CRAMP; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG RESPONSE; FATIGUE; HUMAN; MALE; METASTASIS; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; TACHYCARDIA; THROMBOSIS; VOMITING;

AGED; AGED, 80 AND OVER; ANDROGENS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERIDINES; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 10744230675     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0050     Document Type: Article

References (30)

1. Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., and Thun, M. J. Cancer statistics, 2003. CA - Cancer J. Clin., 53: 5-26, 2003.
2. Harper, J. W., and Adams, P. D. Cyclin-dependent kinases. Chem. Rev., 101: 2511-2526, 2001.
3. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000.
4. Maik, R. G., Kattice, S. L., Bhat, S. V., Alreja, B., DeSouza, N. J., and Rupp, R. H. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from dysoloxylum binectiferum: isolation, structure and total synthesis. Tetrahedron, 44: 2081-2086, 1988.
5. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. Growth inhibition with reversible cell-cycle arrest of carcinoma cells by flavone L86-8275. J. Natl. Cancer Inst. (Bethesda), 84: 1736-1740, 1992.
6. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., and Sausville, E. A. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
7. Bible, K. C., and Kaufman, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in non-cycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
8. Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P., and Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 3: 1467-1472, 1997.
9. Worland, P. J., Kaur, G., and Stetler-Stevenson, M. Alteration of the phosphorylation state or p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem. Pharmacol., 46: 1831-1840, 1993.
10. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E., and Worland, P. J. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
11. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
12. Sedlacek, H. H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewisc, M., Parker, B., Carlson, B., Smith, A., Senderowisc, A., and Sausville, E. A. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9: 1143-1168, 1996.
13. Thomas, J. P., Tutsch, K. D., Cleary, J. F., Bailey, H. H., Arzoomanian, R., Alberti, D., Simon, K., Feierabend, C., Binger, C., Marnocha, R., Dresen, A., and Wilding, G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother. Pharmacol., 50: 465-472, 2002.
14. Senderowisc, A. M., Headlee, D., Stinson, S. F., Lush, R. F., Kalil, N., Villaba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998.
15. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., and Kelsen, D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol., 19: 1985-1992, 2001.
16. Shapiro, G. I., Supko, J. G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P. F., Muzikansky, A., Wright, J. J., Lynch, T. J., Jr., and Rollins, B. J. A Phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin. Cancer Res., 7: 1590-1599, 2001.
17. Aklilu, M., Kindler, H. L., Donehower, R. C., Mani, S., and Vokes, E. E. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann. Oncol., 14: 1270-1273, 2003.
18. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol. 18: 371-375, 2000.
19. Simon, R. Optimal two-stage design for Phase II clinical trials. Control Clin. Trials, 10: 1-10, 1989.
20. Kaplan, E., and Meier, R. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481 1958.
21. Innocenti, F., Stadler W. M., Iyer, L., Ramirez J. Vokes E. E., and Ratain, M. K. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin. Cancer Res., 6: 3400-3405, 2000.
22. Kahn, M. E., Senderowisc, A., Sausville, E. A., and Barrett, K. E. Possible mechanism of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clin. Cancer Res., 7: 343-349, 2001.
23. Li, Y., Chinmni, S. R., Senderowisc, A. M., and Sarkar, F. H. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int. J. Oncol., 17: 755-759, 2000.
24. Drees, M., Dengler, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E. A., and Fiebig, H. H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3: 273-279 1997.
25. Lin, T. S., Howard O. M., Neuberg D. S., Kim, H. H., and Shipp, M. A. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk. Lymphoma, 43: 793-797, 2002.
26. Kouroukis, C. T., Belch, A., Crump, M., Eisenhauer, E., Gascoyne, R. D., Meyer, R., Lahmann, R., Lopez, P., Powers, J., Turner, R., and Connors, J. M. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a Phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 21: 1740-1745, 2003.
27. Becouarn, Y., and Rougier, P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Seminars in Oncol., 25 (2 Suppl. 5): 23-31, 1998.
28. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 57: 3375-3380, 1997.
29. Jung, C., Motwani, M., and Schwartz, G. K. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res., 7: 2537-2544, 2001.
30. Schwartz, G. K., O'Reilly, E., Ilson, D., Saltz, L., Sharma, S., Tong, W., Maslak, P., Stoltz, M., Eden, L., Perkins, P., Endres, S., Barazzoul, J., Spriggs, D., and Kelsen, D. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J. Clin. Oncol., 20: 2157-2170, 2002.